Michael S. Glickman, MD
Research FocusPhysician-scientist Michael Glickman investigates the physiology and pathogenic mechanisms of mycobacteria, including regulated intramembrane proteolysis (the Rip1 pathway); double-strand-break repair and associated DNA damage responses; and cell envelope biosynthesis.
EducationMD, Columbia University College of Physicians and Surgeons
- Wipperman MF, Heaton BE, Nautiyal A, Adefisayo O, Evans H, Gupta R, van Ditmarsch D, Soni R, Hendrickson R, Johnson J, Krogan N, Glickman MS. Mycobacterial Mutagenesis and Drug Resistance Are Controlled by Phosphorylation- and Cardiolipin-Mediated Inhibition of the RecA Coprotease. Mol Cell. 2018 Aug 22. pii: S1097-2765(18)30606-3. doi: 10.1016/j.molcel.2018.07.037. [Epub ahead of print] PubMed
- Redelman-Sidi, G., Iyer, G., Solit, D., and Glickman, M.S. Oncogenic activation of Pak1 dependent Macropinocytosis pathway determines BCG entry into bladder cancer cells. Cancer Res. 2013 Feb 1;73(3):1156-67.